ELRIG Drug Discovery 2026 has ended. This guide stays up as the record of who was there. Next: ELRIG DD 2027, Oct 19–20, 2027 in Liverpool
Radioligands and bioconjugates at ELRIG Drug Discovery 2026
Oct 14–15, 2026 London, UK ~3k attendees Website
12 organizations at ELRIG Drug Discovery 2026 present work in radioligands and bioconjugates: 5 drug developers, 5 technology and service providers and 2 academic, government and non-profit bodies. Between them they bring 21 presentations to the program. Most represented: AstraZeneca, Cancer Research Horizons and Medicines Discovery Catapult. As of Oct 8, 2026.
Format
Top represented
Showing 1–12 of 12 organizations
| Organization | ELRIG Drug Discovery 2026 Attendance |
|---|---|
AstraZeneca Cambridge, UK | ◆Partner |
Global biopharmaceutical company discovering and developing medicines in oncology, rare disease, and cardiovascular, renal, metabolic and respiratory disease. | Booth Exhibiting at Booth CZ01 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Chair Wed Oct 14 11:15am–11:20am Track Chair - CRISPR/Cas technologies from discovery to therapeutic application How CRISPR gene editing is used from finding drug targets to engineering cell and gene therapies, and where it may go next. Chair Wed Oct 14 11:15am–11:20am Track Chair - Next-gen biophysics How biophysics has shaped drug discovery from checking targets to refining lead compounds, and how newer methods can speed programmes up. Talk Wed Oct 14 11:20am–11:50am Talk Wed Oct 14 11:50am–12:20pm Automating In Vivo Antibody Discovery How a manual B-cell processing workflow was automated to reduce operator variability and raise throughput while preserving cell quality. Talk Wed Oct 14 12:20pm–12:50pm Talk Wed Oct 14 2:40pm–3:10pm Talk Wed Oct 14 3:10pm–3:45pm To PhD or not to PhD? Navigating Life Sciences careers as an ECP Whether early career scientists gain more from a doctorate or from hands-on experience, and how people actually build life science careers. Panel Wed Oct 14 4:30pm–5:00pm Talk Wed Oct 14 4:30pm–5:00pm Talk Thu Oct 15 12:40pm–1:10pm Talk Thu Oct 15 3:30pm–4:00pm |
Cancer Research Horizons London, UK | |
Innovation arm of Cancer Research UK, turning academic cancer research into drugs, diagnostics and start-ups through partnerships and licensing. | Booth Exhibiting at Booth C24 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Chair Wed Oct 14 11:15am–11:20am Track Chair - Targeted potency: Advances in radioligands and bioconjugates How radioligand therapies and bioconjugates deliver toxic payloads more precisely and safely to cancers that were once hard to treat. |
Medicines Discovery Catapult Alderley Park, UK | |
UK national centre helping drug discovery entrepreneurs validate ideas and de-risk investment through its expertise, technology and national programmes. | Booth Exhibiting at Booth G28 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Talk Wed Oct 14 4:15pm–4:30pm Advancing Drug Discovery Through Radiopharmaceutical Innovation Why radioactive drugs that both image and treat tumours can confirm a drug reaches its target, and what manufacturing hurdles remain. |
WuXi AppTec Shanghai, China | ◆Conference Partner |
Global CRDMO providing integrated research, development and manufacturing services to pharma and biotech across Asia, Europe and North America. | Booth Exhibiting at Booth H03, H10 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Talk Wed Oct 14 11:50am–12:20pm Integrated Discovery of Targeted Delivery Ligands for Oligonucleotide Therapeutics Finding ring-shaped peptides that bind receptors on brain and muscle cells and carry attached siRNA into them to silence target genes. Talk Wed Oct 14 2:30pm–2:40pm |
Lonza Basel, Switzerland | |
Swiss life science group; its Bioscience unit supplies cell culture and discovery tools, quality control tests and biomanufacturing software. | Booth Exhibiting at Booth J25 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Talk Wed Oct 14 12:20pm–12:50pm |
Artios Pharma Cambridge, UK | |
Develops DNA damage response medicines for cancer, including small molecules and payloads for antibody-drug conjugates. | Talk Wed Oct 14 4:30pm–5:00pm |
Develops pre|CISION peptide drug conjugates whose cytotoxic payloads are released when FAP cleaves them in the tumour microenvironment. | |
Bicycle Therapeutics Cambridge, UK | |
Develops medicines from bicyclic peptides, including toxin and radionuclide conjugates for solid tumours. | |
Iksuda Therapeutics Newcastle, UK | |
Develops antibody-drug conjugates for hard-to-treat cancers, including a new protein-alkylating payload class. | Talk Wed Oct 14 2:00pm–2:30pm |
Fluorochem Glossop, UK | |
Long-established chemicals and building-block supplier, now also offering CRO and CDMO services for ADCs, small molecules, peptides and PROTACs. | Booth Exhibiting at Booth G02 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm |
Syntopia Paris, France | |
Paris start-up running perfused 3D tumour cultures in multiwell microfluidic plates to predict how ADCs and other therapies behave in human tissue. | Booth Exhibiting (no floor booth listed) Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm Exhibiting in the Breakthrough Zone (start-ups and emerging companies) |
Vector Laboratories Newark, CA | |
Makes reagents for detecting and visualising proteins and glycans, bioconjugation linkers and dyes, and offers recombinant antibody engineering services. | Booth Exhibiting at Booth S04 Wed, Oct 148:00am–7:00pmThu, Oct 158:00am–4:00pm |
Instantly find 20 buyers in radioligands and bioconjugates
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ELRIG Drug Discovery 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by ELRIG. Submit a correction